open access

Vol 5, No 6 (2004): Practical Diabetology
Original articles (submitted)
Published online: 2005-02-02
Get Citation

Apoptosis inhibitor sFas expression and acute hyperglycemia in type 2 diabetes

Marzena Dworacka
Diabetologia Praktyczna 2004;5(6):311-316.

open access

Vol 5, No 6 (2004): Practical Diabetology
Original articles (submitted)
Published online: 2005-02-02

Abstract

INTRODUCTION. Apoptosis occuring via Fas/FasL interaction is one from the reasons of macroangiopathy. The soluble receptor Fas (sFas) is thought to be an inhibitor of apoptosis. In type 2 diabetic patients apoptosis is determined by the level of metabolic compensation. The epidemiological studies from last few years revealed that postprandial, so acute, hyperglycemia plays the dominant role in coronary heart disease development. We aimed to evaluate if metabolic control and acute hyperglycemic episodes especially, can influence sFas serum level.
MATERIAL AND METHODS. The total of 49 persons were examined, including 29 type 2 diabetic patients with concomitant coronary heart disease, 10 patients with coronary heart disease only and 10 healthy persons. The plasma level of 1.5-anhydro-D-glucitol was estimated as the marker of acute hyperglycemia. The serum sFas levels were measured together with routine metabolic parameters (fasting glycemia, HbA1c, total cholesterol and HDL, and LDL cholesterol fractions levels, triglyceride serum concentration).
RESULTS. The sFas serum level was significantly higher in patients with diabetes type 2 than in patients with coronary heart disease only and higher than sFas level in controls. The sFas serum concentration in type 2 diabetic patients was correlated only with 1.5-anhydro-D-glucitol concentration.
CONCLUSION. The short-term hyperglycemic episodes, in opposition to chronic hyperglycemia, are related to lower expression of antiapoptotic factor sFas.

Abstract

INTRODUCTION. Apoptosis occuring via Fas/FasL interaction is one from the reasons of macroangiopathy. The soluble receptor Fas (sFas) is thought to be an inhibitor of apoptosis. In type 2 diabetic patients apoptosis is determined by the level of metabolic compensation. The epidemiological studies from last few years revealed that postprandial, so acute, hyperglycemia plays the dominant role in coronary heart disease development. We aimed to evaluate if metabolic control and acute hyperglycemic episodes especially, can influence sFas serum level.
MATERIAL AND METHODS. The total of 49 persons were examined, including 29 type 2 diabetic patients with concomitant coronary heart disease, 10 patients with coronary heart disease only and 10 healthy persons. The plasma level of 1.5-anhydro-D-glucitol was estimated as the marker of acute hyperglycemia. The serum sFas levels were measured together with routine metabolic parameters (fasting glycemia, HbA1c, total cholesterol and HDL, and LDL cholesterol fractions levels, triglyceride serum concentration).
RESULTS. The sFas serum level was significantly higher in patients with diabetes type 2 than in patients with coronary heart disease only and higher than sFas level in controls. The sFas serum concentration in type 2 diabetic patients was correlated only with 1.5-anhydro-D-glucitol concentration.
CONCLUSION. The short-term hyperglycemic episodes, in opposition to chronic hyperglycemia, are related to lower expression of antiapoptotic factor sFas.
Get Citation

Keywords

diabetes type 2; apoptosis; acute hyperglycemia; sFas

About this article
Title

Apoptosis inhibitor sFas expression and acute hyperglycemia in type 2 diabetes

Journal

Clinical Diabetology

Issue

Vol 5, No 6 (2004): Practical Diabetology

Pages

311-316

Published online

2005-02-02

Bibliographic record

Diabetologia Praktyczna 2004;5(6):311-316.

Keywords

diabetes type 2
apoptosis
acute hyperglycemia
sFas

Authors

Marzena Dworacka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl